Tumor cell death induced by topoisomerase-targeting drugs

Annual Review of Pharmacology and Toxicology

Volumn 41, Issue , 2001, Pages 53-77

  Li, T K ^a   Liu, L F ^a  

^a RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

Apoptosis; Camptothecin; SUMO; Topoisomerase; Ubiquitin

Indexed keywords

9 AMINO 20 CAMPTOTHECIN; CAMPTOTHECIN; CAMPTOTHECIN DERIVATIVE; DNA TOPOISOMERASE; DNA TOPOISOMERASE INHIBITOR; IRINOTECAN; PROTEASOME; TOPOTECAN; UBIQUITIN; UNCLASSIFIED DRUG;

APOPTOSIS; CANCER CELL; CANCER INHIBITION; CELL DEATH; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG TARGETING; ENZYME MECHANISM; GENETIC STABILITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; TRANSCRIPTION REGULATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL DEATH; DNA TOPOISOMERASES, TYPE I; ENZYME INHIBITORS; HUMANS; NEOPLASMS;

EID: 0035029153     PISSN: 03621642     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.pharmtox.41.1.53     Document Type: Review

References (159)

1. BNA topoisomerases: Essential enzymes and lethal targets
2. DNA topoisomerase poisons as antitumor drugs
3. Mechanisms of cell killing by drugs that trap covalent complexes between DNA topoisomerases and DNA
4. Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme
5. DNA topoisomerases
6. Mitotic chromosome condensation in the rDNA requires TRF4 and DNA topoisomerase I in Saccharomyces cerevisiae
7. The essential roles of DNA topoisomerase I in Drosophila melanogaster
8. CDNA cloning of human DNA topoisomerase I: Catalytic activity of a 67.7-kDa carboxyl-terminal fragment
9. Human topoisomerase I is encoded by a single-copy gene that maps to chromosome region 20q12-13.2
10. The domain organization of human topoisomerase I
11. A model for the mechanism of human topoisomerase I
12. Crystal structures of human topoisomerase I in covalent and noncovalent complexes with DNA
13. DNA topoisomerase I is essential in Drosophila melanogaster
14. Targeted disruption of the mouse topoisomerase I gene by camptothecin selection
15. Identification of a nucleolin binding site in human topoisomerase I
16. Topoisomerase I associates specifically with simian virus 40 large-T-antigen double hexamer-origin complexes
17. The interaction between p53 and DNA topoisomerase I is regulated differently in cells with wild-type and mutant p53
18. Interaction between the N-terminus of human topoisomerase I and SV40 large T antigen
19. A role for the amino terminus of human topoisomerase I
20. Identification of human DNA topoisomerase I as a cofactor for activator-dependent transcription by RNA polymerase II
21. The specific interactions of HMG 1 and 2 with negatively supercoiled DNA are modulated by their acidic C-terminal domains and involve cysteine residues in their HMG 1/2 boxes
22. Simian virus 40 large T antigen binds to topoisomerase I
23. SUMO-1 conjugation to topoisomerase I: A possible repair response to topoisomerase-mediated DNA damage
24. The Werner syndrome gene product co-purifies with the DNA replication complex and interacts with PCNA and topoisomerase I
25. Mammalian DNA topoisomerase IIIalpha is essential in early embryogenesis
26. Human TOP3: A single-copy gene encoding DNA topoisomerase III
27. The Bloom's syndrome gene product interacts with topoisomerase III
28. A new human topoisomerase III that interacts with SGS1 protein
29. Cloning of cDNA encoding a novel mouse DNA topoisomerase III (Topo IIIbeta) possessing negatively supercoiled DNA relaxing activity, whose message is highly expressed in the testis
30. Cloning and characterization of Drosophila topoisomerase IIIbeta. Relaxation of hypernegatively supercoiled DNA
31. Human RecQ5beta, a large isomer of RecQ5 DNA helicase, localizes in the nucleoplasm and interacts with topoisomerases 3alpha and 3beta
32. Homologous recombination is responsible for cell death in the absence of the sgs1 and srs2 helicases
33. RecQ helicase and topoisomerase III comprise a novel DNA strand passage function: A conserved mechanism for control of DNA recombination
34. Isolation of cDNA clones encoding the beta isozyme of human DNA topoisomerase II and localisation of the gene to chromosome 3p24
35. Cloning and sequencing of cDNA encoding human DNA topoisomerase II and localization of the gene to chromosome region 17q21-22
36. Proliferation-dependent regulation of DNA topoisomerase II in cultured human cells
37. Topoisomerase II is a structural component of mitotic chromosome scaffolds
38. Proliferation- and cell cycle-dependent differences in expression of the 170 kilodalton and 180 kilodalton forms of topoisomerase II in NIH-3T3 cells
39. DNA topoisomerase IIbeta and neural development
40. DNA topoisomerase II expression, stability, and phosphorylation in two VM-26-resistant human leukemic CEM sublines
41. Selective use of an alternative stop codon and polyadenylation signal within intron sequences leads to a truncated topoisomerase II alpha messenger RNA and protein in human HL-60 leukemia cells selected for resistance to mitoxantrone
42. Murine transgenic cells lacking DNA topoisomerase IIbeta are resistant to acridines and mitoxantrone: Analysis of cytotoxicity and cleavable complex formation
43. Plant antitumor agents. I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata
44. Treatment of malignant melanoma with camptothecin (NSC-100880)
45. Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): Correlation with preclinical studies
46. Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin
47. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I
48. DNA topoisomerase-targeting antitumor drugs can be studied in yeast
49. Characterization of a mammalian mutant with a camptothecin resistant DNA topoisomerase I
50. Topoisomerase I-targeting drugs: New developments in cancer pharmacology
51. Topoisomerase I inhibitor: Selectivity and cellular resistance
52. Homocamptothecin, an E-ring modified camptothecin with enhanced lactone stability, retains topoisomerase I-targeted activity and antitumor properties
53. Homocamptothecin, an E-ring-modified camptothecin, exerts more potent antiproliferative activity than other topoisomerase I inhibitors in human colon cancers obtained from surgery and maintained in vitro under histotypical culture conditions
54. Potent topoisomerase I inhibition by novel silatecans eliminates glioma proliferation in vitro and in vivo
55. On the mechanism of topoisomerase I inhibition by camptothecin: Evidence for binding to an enzyme-DNA complex
56. Irreversible trapping of the DNA-topoisomerase I covalent complex. Affinity labeling of the camptothecin binding site
57. New technique for uncoupling the cleavage and religation reactions of eukaryotic topoisomerase I. The mode of action of camptothecin at a specific recognition site
58. Interaction of an alkylating camptothecin derivative with a DNA base at topoisomerase I-DNA cleavage sites
59. Inhibition of eukaryotic DNA topoisomerase I and II activities by indoloquinolinedione derivatives
60. Human topoisomerase I poisoning by protoberberines: Potential roles for both drug-DNA and drug-enzyme interactions
61. Site specific topoisomerase I-mediated DNA cleavage induced by nogalamycin: A potential role of ligand-induced DNA bending at a distal site
62. Enkaryotic topoisomerase I-DNA interaction is stabilized by helix curvature
63. DNA minor groove-binding ligands: A different class of mammalian DNA topoisomerase I inhibitors
64. A terbenzimidazole that preferentially binds and conformationally alters structurally distinct DNA duplex domains: A potential mechanism for topoisomerase I poisoning
65. Minor groovedirected and intercalative ligand-DNA interactions in the poisoning of human DNA topoisomerase I by protoberberine analogs
66. Differential poisoning of topoisomerases by menogaril and nogalamycin dictated by the minor groove-binding nogalose sugar
67. DNA minor groove binding-directed poisoning of human DNA topoisomerase I by terbenzimidazoles
68. Benzo[a]pyrene diol epoxide adducts in DNA are potent suppressors of a normal topoisomerase I cleavage site and powerful inducers of other topoisomerase I cleavages
69. Induction of topoisomerase I cleavage complexes by 1-beta-D-arabinofuranosylcytosine (ara-C) in vitro and in ara-C-treated cells
70. Effects of uracil incorporation, DNA mismatches, and abasic sites on cleavage and religation activities of mammalian topoisomerase I
71. Trapping of mammalian topoisomerase I and recombinations induced by damaged DNA containing nicks or gaps. Importance of DNA end phosphorylation and camptothecin effects
72. Induction of topoisomerase I cleavage complexes by the vinyl chloride adduct 1, N6-ethenoadenine
73. Induction of reversible complexes between eukaryotic DNA topoisomerase I and DNA-containing oxidative base damages 7,8-dihydro-8-oxoguanine and 5-hydroxycytosine
74. Involvement of nucleic acid synthesis in cell killing mechanisms of topoisomerase poisons
75. Arrest of replication forks by drugstabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin
76. The involvement of active DNA synthesis in camptothecin-induced G2 arrest: Altered regulation of p34cdc2/cyclin B
77. Interaction between replication forks and topoisomerase I-DNA cleavable complexes: Studies in a cellfree SV40 DNA replication system
78. Human DNA topoisomerase I-mediated cleavage and recombination of duck hepatitis B virus DNA in vitro
79. NT-kappaB activation by camptothecin. A linkage between nuclear DNA damage and cytoplasmic signaling events
80. DNA strand breaks: The DNA template alterations that trigger p53-dependent DNA damage response pathways
81. Topoisomerase poisons activate the transcription factor NFkappaB in ACH-2 and CEM cells
82. Replication-mediated DNA damage by camptothecin induces phosphorylation of RPA by DNA-dependent protein kinase and dissociates RPA:DNA-PK complexes
83. The topoisomerase I poison camptothecin generates a Chk1-dependent DNA damage checkpoint signal in fission yeast
84. Detection of apoptosis induced by topoisomerase inhibitors and serum deprivation in syrian hamster embryo cells
85. Complex response of breast epithelial cell lines to topoisomerase inhibitors
86. Induction of neuronal apoptosis by camptothecin, an inhibitor of DNA topoisomerase-I: Evidence for cell cycle-independent toxicity
87. Processing of topoisomerase I cleavable complexes into DNA damage by transcription
88. Detection of apoptosis induced by topoisomerase inhibitors and serum deprivation in syrian hamster embryo cells
89. Apoptotic response to camptothecin and 7-hydroxystaurosporine (UCN-01) in the 8 human breast cancer cell lines of the NCI Anticancer Drug Screen: Multifactorial relationships with topoisomerase I, protein kinase C, Bcl-2, p53, MDM-2 and caspase pathways
90. P53 status plays no role in radiosensitizing effects of SN-38, a camptothecin derivative
91. Apoptosis, p53, and tumor cell sensitivity to anticancer agents
92. Effects of camptothecin on RNA synthesis in leukemia L1210 cells
93. Camptothecin effects on DNA synthesis in routine leukemia cells
94. Ribosome formation is blocked by camptothecin, a reversible inhibitor of RNA synthesis
95. Studies on camptothecin. I. Effects of nucleic acid and protein synthesis
96. Involvement of DNA topoisomerase I in transcription of human ribosomal RNA genes
97. Localization of specific topoisomerase I inter-actions within the transcribed region of active heat shock genes by using the inhibitor camptothecin
98. Camptothecin-induced in vivo topoisomerase I cleavages in the transcriptionally active tyrosine aminotransferase gene
99. Camptothecinstabilized topoisomerase I-DNA adducts cause premature termination of transcription
100. Hypersensitivity of Cockayne's syndrome cells to camptothecin is associated with the generation of abnormally high levels of double strand breaks in nascent DNA
101. Camptothecin induction of a time- and concentration-dependent decrease of topoisomerase I and its implication in camptothecin activity
102. Ubiquitin-dependent destruction of topoisomerase I is stimulated by the antitumor drug camptothecin
103. Topoisomerase I-related parameters and camptothecin activity in the colon carcinoma cell lines from the National Cancer Institute anticancer screen
104. SUMO-1 conjugation to topoisomerase I: A possible repair response to topoisomerase-mediated DNA damage
105. SUMO-1 conjugation to human DNA topoisomerase II isozyme
106. Functional heterogeneity of small ubiquitin-related protein modifiers SUMO-1 versus SUMO-2/3
107. Plasmid linking number change induced by topoisomerase I-mediated DNA damage
108. Activation of topoisomerase II-mediated excision of chromosomal DNA loops during oxidative stress
109. Double stranded cleavage/religation reaction of eucaryotic topoisomerase II: Evidence for a nicked DNA intermediate
110. Induction of DNA topoisomerase II-mediated DNA cleavage by beta-lapachone and related naphthoquinones
111. Beta-Lapachone, a novel DNA topoisomerase I inhibitor with a mode of action different from camptothecin
112. DNA topoisomerase II-mediated interaction of doxorubicin and daunorubicin congeners with DNA
113. Intercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II
114. Mechanism of antitumor drug action: Poisoning of mammalian DNA topoisomerase II on DNA by 4′-(9-acridinyl-amino)-methanesulfonm-anisidide
115. Involvement of intracellular ATP in cytotoxicity of topoisomerase II-targetting antitumor drugs
116. Mutations of human topoisomerase II alpha affecting multidrug resistance and sensitivity
117. Antitumor bisdioxopiperazines inhibit yeast DNA topoisomerase II by trapping the enzyme in the form of a closed protein clamp
118. Altered DNA topoisomerase II in multidrug resistance
119. Barrett's esophagus. Reducing the risk of progression to adenocarcinoma
120. DNA abasic lesions in a different light: Solution structure of an endogenous topoisomerase II poison
121. Spontaneous DNA damage stimulates topoisomerase II-mediated DNA cleavage
122. Topoisomerase II-mediated DNA cleavage and religation in the absence of base pairing. Abasic lesions as a tool to dissect enzyme mechanism
123. Topoisomerase II site-directed alkylation of DNA by psorospermin and its effect on topoisomerase II-mediated DNA cleavage
124. Sensitivity of human type II topoisomerases to DNA damage: Stimulation of enzyme-mediated DNA cleavage by abasic, oxidized and alkylated lesions
125. Cytosine arabinoside lesions are position-specific topoisomerase II poisons and stimulate DNA cleavage mediated by the human type II enzymes
126. Inhibition of DNA topoisomerase II by ICRF-193 induces polyploidization by uncoupling chromosome dynamics from other cell cycle events
127. DNA topoisomerase II is the molecular target of bisdioxopiperazine derivatives ICRF-159 and ICRF-193 in Saccharomyces cerevisiae
128. Interactions between DNA helicases and frozen topoisomerase IV-quinolone-DNA ternary complexes
129. Multiple roles of spo11 in meiotic chromosome behavior
130. Meiosis-specific formation of joint DNA molecules containing sequences from homologous chromosomes
131. Meiosis-specific DNA doublestrand breaks are catalyzed by Spo11, a member of a widely conserved protein family
132. The nuclease activity of Mre11 is required for meiosis but not for mating type switching, end joining, or telomere maintenance
133. Secondary leukemias induced by topoisomerase-targeted drugs
134. Mechanism-based chemopreventive strategies against etoposide-induced acute myeloid leukemia: Free radical/antioxidant approach
135. Acute myelogenous leukemia after treatment for malignant germ cell tumors in children
136. Are topoisomerase II inhibitor-induced micronuclei in vitro a predictive marker for the compounds' ability to cause secondary leukemias after treatment?
137. Dietary bioflavonoids induce cleavage in the MLL gene and may contribute to infant leukemia
138. DNA cleavage within the MLL breakpoint cluster region is a specific event which occurs as part of higher-order chromatin fragmentation during the initial stages of apoptosis
139. Maternal diet and infant leukemia: A role for DNA topoisomerase II inhibitors?
140. Site-specific DNA cleavage by mammalian DNA topoisomerase II induced by novel flavone and catechin derivatives
141. Integration of simian virus 40 into cellular DNA occurs at or near topoisomerase II cleavage hot spots induced by VM-26 (teniposide)
142. Illegitimate recombination mediated by calf thymus DNA topoisomerase II in vitro
143. DNA topoisomerase-mediated illegitimate recombination
144. DNA nick processing by exonuclease and polymerase activities of bacteriophage T4 DNA polymerase accounts for acridine-induced mutation specificities in T4
145. Hotspot sites for acridine-induced frameshift mutations in bacteriophage T4 correspond to sites of action of the T4 type II topoisomerase
146. Hypersensitivity of Ku80-deficient cell lines and mice to DNA damage: The effects of ionizing radiation on growth, survival, and development
147. p53 status, DNA double-strand break repair proficiency, and radiation response of mouse lymphoid and myeloid cell lines
148. DNA damage signals induction of fas ligand in tumor cells
149. Differential induction of apoptosis in undifferentiated and differentiated HL-60 cells by DNA topoisomerase I and II inhibitors
150. Topoisomerase II-reactive chemotherapeutic drugs induce apoptosis in thymocytes
151. CAR1, a TNFR-related protein, is a cellular receptor for cytopathic avian leukosissarcoma viruses and mediates apoptosis
152. Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO-1- and TNF receptor-induced cell death
153. Ischemic cell death in brain neurons
154. The role of calcium, pH, and cell proliferation in the programmed (apoptotic) death of androgen-independent prostatic cancer cells induced by thapsigargin
155. Store depletion and calcium influx
156. Extracellular acidification induces human neutrophil activation
157. An acidic environment leads to p53 dependent induction of apoptosis in human adenoma and carcinoma cell lines: Implications for clonal selection during colorectal carcinogenesis